Beximco Pharma is a leading manufacturer and exporter of medicines based in Bangladesh. Incorporated in 1976, the Company started its operation by importing products from Bayer, Germany and Upjohn, USA and selling them in the local market. In 1980, Beximco Pharma began manufacturing of these products under licensing arrangement and in 1983 launched its own formulation brands. Since its inception, the Company remains committed to health and wellbeing of people across all the continents by providing access to contemporary medicines. Company's broad portfolio of generics encompasses diverse delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, nasal sprays, nebuliser solutions, sterile ophthalmic drops, insulins, injectables including prefilled syringes, oral soluble films etc. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies. Beximco Pharma′s state-of-the-art manufacturing facilities are certified by global regulatory authorities of USA, Europe, Australia, Canada, GCC and Brazil, among others and it has a geographic footprint in more than 50 countries.
The Company has won the National Export (Gold) trophy for 5 times. It also won the highly prestigious SCRIP Award as the “Best Pharma Company in an Emerging Market” and also won CPhI Pharma Awards 2020 for “Innovation in Response to COVID-19.”
In 2018, Beximco Pharma acquired majority stake in Nuvista Pharma (formerly Organon Bangladesh), a leading hormone and steroid manufacturer in the country.
More than 5,500 employees are driving the company towards achieving its aspiration to be among the most admired companies in the world.
For the year ended 30 June 2020, Beximco Pharma’s reported revenue was Bangladesh Taka ("BDT") 25,611.9m / £245.5m (12.3% growth) with reported profit after tax was BDT 3,544.4m / £34.0m (16.6% growth).
For the half year ended 31 December 2020, Beximco Pharma’s reported revenue was Bangladesh Taka ("BDT") 14,400.2m / £125.8m (15.2% growth) with reported profit after tax was BDT 2,226.3m / £19.4m (29.8% growth).
For more information, visit www.beximcopharma.com
Buy BXP Stock Free BXP Stock Alerts